Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label PK, safety, and tolerability study of TLC599 in Japanese subjects with knee osteoarthritis
jRCT2031260147Phase 1Recruiting
- Sponsor
- Taiwan Liposome Company
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TLC599 in knee osteoarthritis (OA), sponsored by Taiwan Liposome Company. Primary endpoint: Pharmacokinetics of dexamethasone phosphate and dexamethasone. Started May 2026; status: recruiting.
02
Drugs
TLC599
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCT2031260147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260147.